You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAmoxapine
Accession NumberDB00543  (APRD00142)
TypeSmall Molecule
GroupsApproved
DescriptionAmoxapine, the N-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Amoxapine may be used to treat neurotic and reactive depressive disorders, endogenous and psychotic depression, and mixed symptoms of depression and anxiety or agitation.
Structure
Thumb
Synonyms
2-Chloro-11-(1-piperazinyl)dibenz(b,F)(1,4)oxazepine
Amoxapin
Amoxapina
Amoxapinum
Amoxepine
Desmethylloxapin
External Identifiers
  • CL 67772
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Asendin - Tab 100mgtablet100 mgoralWyeth Ayerst Canada Inc.1999-04-122002-06-10Canada
Asendin - Tab 25mgtablet25 mgoralWyeth Ayerst Canada Inc.1997-02-042000-08-02Canada
Asendin - Tab 50mgtablet50 mgoralWyeth Ayerst Canada Inc.1997-04-292001-12-12Canada
Asendin Tab 100mgtablet100 mgoralLederle Cyanamid Canada Inc.1981-12-311999-04-12Canada
Asendin Tab 25mgtablet25 mgoralLederle Cyanamid Canada Inc.1981-12-311997-08-14Canada
Asendin Tab 50mgtablet50 mgoralLederle Cyanamid Canada Inc.1981-12-311999-04-12Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amoxapinetablet25 mg/1oralActavis Pharma, Inc.1992-08-28Not applicableUs
Amoxapinetablet50 mg/1oralPhysicians Total Care, Inc.2011-05-12Not applicableUs
Amoxapinetablet50 mg/1oralActavis Pharma, Inc.1992-08-28Not applicableUs
Amoxapinetablet100 mg/1oralActavis Pharma, Inc.1992-08-28Not applicableUs
Amoxapinetablet150 mg/1oralActavis Pharma, Inc.1992-08-28Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AdisenKun Wha
AmolifeNot Available
AmoxanWyeth KK
AsendinNot Available
AsendisNot Available
DéfanylEisai
DemoloxWyeth
OxaminePsyco Remedies
OxcapNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIR63VQ857OT
CAS number14028-44-5
WeightAverage: 313.781
Monoisotopic: 313.098189856
Chemical FormulaC17H16ClN3O
InChI KeyInChIKey=QWGDMFLQWFTERH-UHFFFAOYSA-N
InChI
InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2
IUPAC Name
13-chloro-10-(piperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,9,12,14-heptaene
SMILES
ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzoxazepines. These are compounds containing a dibenzoxazepine moiety, which consists of two benzene connected by an oxazepine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzoxazepines
Sub ClassDibenzoxazepines
Direct ParentDibenzoxazepines
Alternative Parents
Substituents
  • Dibenzoxazepine
  • Diaryl ether
  • Imidolactam
  • Benzenoid
  • Piperazine
  • 1,4-diazinane
  • Aryl halide
  • Aryl chloride
  • Tertiary amine
  • Oxacycle
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Carboxylic acid amidine
  • Amidine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. May also be used to treat depression accompanied by anxiety or agitation.
PharmacodynamicsAmoxapine is a tricyclic antidepressant of the dibenzoxazepine class, chemically distinct from the dibenzodiazepines, dibenzocycloheptenes, and dibenzoxepines. It has a mild sedative component to its action. The mechanism of its clinical action in man is not well understood. In animals, amoxapine reduced the uptake of nor-epinephirine and serotonin and blocked the response of dopamine receptors to dopamine. Amoxapine is not a monoamine oxidase inhibitor. Clinical studies have demonstrated that amoxapine has a more rapid onset of action than either amitriptyline or imipramine
Mechanism of actionAmoxapine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).
Related Articles
AbsorptionRapidly and almost completely absorbed from the GI tract. Peak plasma concentrations occur within 1-2 hours of oral administration of a single dose.
Volume of distribution

Widely distributed in body tissues with highest concentrations found in lungs, spleen, kidneys, heart, and brain. Lower concentrations can be detected in testes and muscle.

Protein bindingIn vitro tests show that amoxapine binding to human plasma proteins is approximately 90%.
Metabolism

Amoxapine is almost completely metabolized in the liver to its major metabolite, 8-hydroxyamoxapine, and a minor metabolite, 7-hydroxyamoxapine. Both metabolites are phamacologically inactive and have half-lives of approximately 30 and 6.5 hours, respectively.

SubstrateEnzymesProduct
Amoxapine
Not Available
7-hydroxyamoxapineDetails
Amoxapine
Not Available
8-hydroxyamoxapineDetails
Route of elimination60-69% of a single orally administered dose of amoxapine is excreted in urine, principally as conjugated metabolites. 7-18% of the dose is excrete feces mainly as unconjugated metabolites. Less than 5% of the dose is excreted as unchanged drug in urine.
Half life8 hours
ClearanceNot Available
ToxicityToxic manifestations of amoxapine overdosage differ significantly from those of other tricyclic antidepressants. Serious cardiovascular effects are seldom if ever observed. However, CNS effects, particularly grand mal convulsions, occur frequently, and treatment should be directed primarily toward prevention or control of seizures. Status epilepticus may develop and constitutes a neurologic emergency. Coma and acidosis are other serious complications of substantial amoxapine overdosage in some cases. Renal failure may develop two to five days after toxic overdose in patients who may appear otherwise recovered. Acute tubular necrosis with rhabdomuolysis and myolobinurla is the most common renal complication in such cases. This reaction probably occurs in less than 5% of overdose cases, and typically in those who have experienced multiple seizures.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9928
Blood Brain Barrier+0.988
Caco-2 permeable-0.5488
P-glycoprotein substrateSubstrate0.8068
P-glycoprotein inhibitor IInhibitor0.7622
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterInhibitor0.6414
CYP450 2C9 substrateNon-substrate0.7682
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5168
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5472
Ames testNon AMES toxic0.7277
CarcinogenicityNon-carcinogens0.8159
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9781 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6376
hERG inhibition (predictor II)Inhibitor0.7874
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Sandoz inc
  • Watson laboratories inc
  • Lederle laboratories div american cyanamid co
Packagers
Dosage forms
FormRouteStrength
Tabletoral100 mg/1
Tabletoral150 mg/1
Tabletoral25 mg/1
Tabletoral50 mg/1
Tabletoral100 mg
Tabletoral25 mg
Tabletoral50 mg
Prices
Unit descriptionCostUnit
Amoxapine 30 150 mg tablet Bottle82.15USD bottle
Amoxapine 150 mg tablet2.63USD tablet
Amoxapine 100 mg tablet1.7USD tablet
Amoxapine 50 mg tablet1.02USD tablet
Amoxapine 25 mg tablet0.63USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point175-176Howell, C.F., Hardy, R.A., Jr. and Quinones, N.Q.; US. Patent 3,663,696; May 16, 1972; assigned to American Cyanamid Company Howell, C.F., Hardy, R.A., Jr. and Quinones, N.Q.; U.S. Patent 3,681,357; August 1, 1972; assigned to American Cyanamid Company
logP3.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.171 mg/mLALOGPS
logP2.82ALOGPS
logP3.08ChemAxon
logS-3.3ALOGPS
pKa (Strongest Basic)8.83ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area36.86 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity89.82 m3·mol-1ChemAxon
Polarizability32.82 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-052b-4490000000-6bbd0d2c0c8fe332c636View in MoNA
References
Synthesis Reference

Howell, C.F., Hardy, R.A., Jr. and Quinones, N.Q.; US. Patent 3,663,696; May 16, 1972; assigned to American Cyanamid Company
Howell, C.F., Hardy, R.A., Jr. and Quinones, N.Q.; U.S. Patent 3,681,357; August 1, 1972; assigned to American Cyanamid Company

US3663696
General ReferencesNot Available
External Links
ATC CodesN06AA17
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Amoxapine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Amoxapine.
AbirateroneThe metabolism of Amoxapine can be decreased when combined with Abiraterone.
AcarboseAmoxapine may increase the hypoglycemic activities of Acarbose.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Amoxapine.
AcenocoumarolAmoxapine may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Amoxapine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Amoxapine.
AcetophenazineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Acetophenazine.
Acetylsalicylic acidAmoxapine may increase the antiplatelet activities of Acetylsalicylic acid.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Amoxapine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Amoxapine.
AlbiglutideAmoxapine may increase the hypoglycemic activities of Albiglutide.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Amoxapine.
AlfentanilAlfentanil may increase the serotonergic activities of Amoxapine.
AlfentanilThe risk or severity of adverse effects can be increased when Amoxapine is combined with Alfentanil.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Amoxapine.
AlmotriptanThe risk or severity of adverse effects can be increased when Amoxapine is combined with Almotriptan.
AlogliptinAmoxapine may increase the hypoglycemic activities of Alogliptin.
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Amoxapine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Amoxapine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Amoxapine.
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Amoxapine.
AmiodaroneAmoxapine may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe metabolism of Amoxapine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Amoxapine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Amoxapine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Amoxapine.
AnagrelideAmoxapine may increase the QTc-prolonging activities of Anagrelide.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amoxapine.
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Amoxapine.
Arsenic trioxideAmoxapine may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherAmoxapine may increase the QTc-prolonging activities of Artemether.
ArtemetherThe metabolism of Amoxapine can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Amoxapine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Amoxapine.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Amoxapine.
AtomoxetineThe metabolism of Amoxapine can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Amoxapine.
AzelastineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Amoxapine.
AzithromycinAmoxapine may increase the QTc-prolonging activities of Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Amoxapine.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Amoxapine.
BedaquilineAmoxapine may increase the QTc-prolonging activities of Bedaquiline.
BefunololThe serum concentration of Befunolol can be increased when it is combined with Amoxapine.
BendroflumethiazideAmoxapine may increase the hyponatremic activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the serotonergic activities of Amoxapine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Amoxapine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Amoxapine.
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Amoxapine.
BetaxololThe metabolism of Amoxapine can be decreased when combined with Betaxolol.
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Amoxapine.
BezitramideBezitramide may increase the serotonergic activities of Amoxapine.
BifeprunoxThe risk or severity of adverse effects can be increased when Amoxapine is combined with Bifeprunox.
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Amoxapine.
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Amoxapine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Amoxapine.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.
BrimonidineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Amoxapine.
BromocriptineAmoxapine may increase the hypoglycemic activities of Bromocriptine.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Amoxapine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Amoxapine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Amoxapine.
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Amoxapine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Amoxapine.
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Amoxapine.
BuprenorphineBuprenorphine may increase the serotonergic activities of Amoxapine.
BuprenorphineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Buprenorphine.
BupropionThe metabolism of Amoxapine can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Amoxapine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Amoxapine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Amoxapine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Amoxapine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Amoxapine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Amoxapine.
ButorphanolButorphanol may increase the serotonergic activities of Amoxapine.
ButorphanolThe risk or severity of adverse effects can be increased when Amoxapine is combined with Butorphanol.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Amoxapine.
CanagliflozinAmoxapine may increase the hypoglycemic activities of Canagliflozin.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Amoxapine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Amoxapine.
CarfentanilCarfentanil may increase the serotonergic activities of Amoxapine.
CarfentanilThe risk or severity of adverse effects can be increased when Amoxapine is combined with Carfentanil.
CariprazineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Amoxapine.
CaroxazoneCaroxazone may increase the serotonergic activities of Amoxapine.
CarteololThe serum concentration of Carteolol can be increased when it is combined with Amoxapine.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Amoxapine.
CelecoxibThe metabolism of Amoxapine can be decreased when combined with Celecoxib.
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Amoxapine.
CeritinibAmoxapine may increase the QTc-prolonging activities of Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Amoxapine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Amoxapine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Amoxapine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Amoxapine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Amoxapine.
ChloroquineAmoxapine may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe metabolism of Amoxapine can be decreased when combined with Chloroquine.
ChlorothiazideAmoxapine may increase the hyponatremic activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Amoxapine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Amoxapine.
ChlorpropamideAmoxapine may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Amoxapine.
ChlorthalidoneAmoxapine may increase the hyponatremic activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Amoxapine.
CholecalciferolThe metabolism of Amoxapine can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Amoxapine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Amoxapine can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Amoxapine.
CiprofloxacinAmoxapine may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideAmoxapine may increase the QTc-prolonging activities of Cisapride.
CitalopramThe risk or severity of adverse effects can be increased when Amoxapine is combined with Citalopram.
CitalopramThe metabolism of Amoxapine can be decreased when combined with Citalopram.
ClarithromycinAmoxapine may increase the QTc-prolonging activities of Clarithromycin.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Amoxapine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Amoxapine.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Amoxapine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Amoxapine.
ClomipramineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Amoxapine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Amoxapine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amoxapine.
ClotrimazoleThe metabolism of Amoxapine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Amoxapine.
CobicistatThe serum concentration of Amoxapine can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Amoxapine.
CodeineCodeine may increase the serotonergic activities of Amoxapine.
CodeineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Codeine.
CrizotinibAmoxapine may increase the QTc-prolonging activities of Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Amoxapine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Amoxapine.
CyproheptadineThe therapeutic efficacy of Amoxapine can be decreased when used in combination with Cyproheptadine.
CyproheptadineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Amoxapine.
DapagliflozinAmoxapine may increase the hypoglycemic activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Amoxapine.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Amoxapine.
DarifenacinThe metabolism of Amoxapine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Amoxapine can be increased when it is combined with Darunavir.
DelavirdineThe metabolism of Amoxapine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Amoxapine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Amoxapine.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Amoxapine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Amoxapine.
DesmopressinThe risk or severity of adverse effects can be increased when Amoxapine is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Amoxapine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Amoxapine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Amoxapine.
DextromethorphanAmoxapine may increase the serotonergic activities of Dextromethorphan.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Amoxapine.
DextromoramideDextromoramide may increase the serotonergic activities of Amoxapine.
DextromoramideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dextromoramide.
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Amoxapine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dextropropoxyphene.
DezocineDezocine may increase the serotonergic activities of Amoxapine.
DezocineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Amoxapine.
DicoumarolAmoxapine may increase the anticoagulant activities of Dicoumarol.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Amoxapine.
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Amoxapine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dihydrocodeine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Amoxapine.
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Amoxapine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dihydroetorphine.
DihydromorphineDihydromorphine may increase the serotonergic activities of Amoxapine.
DihydromorphineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Amoxapine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Amoxapine.
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Amoxapine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Amoxapine is combined with Diphenoxylate.
DisopyramideAmoxapine may increase the hypoglycemic activities of Disopyramide.
DofetilideAmoxapine may increase the QTc-prolonging activities of Dofetilide.
DolasetronAmoxapine may increase the QTc-prolonging activities of Dolasetron.
DolasetronDolasetron may increase the serotonergic activities of Amoxapine.
DomperidoneAmoxapine may increase the QTc-prolonging activities of Domperidone.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Amoxapine.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Amoxapine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Amoxapine.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.
DoxylamineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Doxylamine.
DPDPEDPDPE may increase the serotonergic activities of Amoxapine.
DPDPEThe risk or severity of adverse effects can be increased when Amoxapine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.
DronedaroneAmoxapine may increase the QTc-prolonging activities of Dronedarone.
DronedaroneThe metabolism of Amoxapine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Amoxapine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Amoxapine.
DulaglutideAmoxapine may increase the hypoglycemic activities of Dulaglutide.
DuloxetineThe metabolism of Amoxapine can be decreased when combined with Duloxetine.
DuloxetineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Amoxapine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Amoxapine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Amoxapine.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Amoxapine.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Amoxapine.
EliglustatAmoxapine may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Amoxapine can be decreased when combined with Eliglustat.
EmpagliflozinAmoxapine may increase the hypoglycemic activities of Empagliflozin.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Amoxapine.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Amoxapine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ergoloid mesylate.
ErgonovineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ergonovine.
ErgotamineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ergotamine.
ErythromycinAmoxapine may increase the QTc-prolonging activities of Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Amoxapine is combined with Escitalopram.
EscitalopramEscitalopram may increase the serotonergic activities of Amoxapine.
EsmololThe serum concentration of Esmolol can be increased when it is combined with Amoxapine.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Amoxapine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Amoxapine.
EthanolAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Amoxapine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amoxapine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Amoxapine.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Amoxapine.
Ethyl biscoumacetateAmoxapine may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Amoxapine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Amoxapine.
EthylmorphineEthylmorphine may increase the serotonergic activities of Amoxapine.
EthylmorphineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Amoxapine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Amoxapine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Amoxapine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Amoxapine.
EtoperidoneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Etoperidone.
EtoperidoneEtoperidone may increase the serotonergic activities of Amoxapine.
EtorphineEtorphine may increase the serotonergic activities of Amoxapine.
EtorphineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Etorphine.
ExenatideAmoxapine may increase the hypoglycemic activities of Exenatide.
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Amoxapine.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Amoxapine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Amoxapine.
FenfluramineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fenfluramine.
FenfluramineFenfluramine may increase the serotonergic activities of Amoxapine.
FentanylFentanyl may increase the serotonergic activities of Amoxapine.
FentanylThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fentanyl.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Amoxapine.
FlecainideAmoxapine may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Amoxapine.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Amoxapine.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Amoxapine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Amoxapine.
FluoxetineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fluoxetine.
FluoxetineFluoxetine may increase the serotonergic activities of Amoxapine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Amoxapine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Amoxapine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Amoxapine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Amoxapine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Amoxapine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Amoxapine.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Amoxapine.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Amoxapine.
FrovatriptanThe risk or severity of adverse effects can be increased when Amoxapine is combined with Frovatriptan.
FurazolidoneFurazolidone may increase the serotonergic activities of Amoxapine.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Amoxapine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Amoxapine.
Gadobenic acidAmoxapine may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Amoxapine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Amoxapine.
GemifloxacinAmoxapine may increase the QTc-prolonging activities of Gemifloxacin.
GliclazideAmoxapine may increase the hypoglycemic activities of Gliclazide.
GlimepirideAmoxapine may increase the hypoglycemic activities of Glimepiride.
GlipizideAmoxapine may increase the hypoglycemic activities of Glipizide.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Amoxapine.
GlyburideAmoxapine may increase the hypoglycemic activities of Glyburide.
GoserelinAmoxapine may increase the QTc-prolonging activities of Goserelin.
GranisetronAmoxapine may increase the QTc-prolonging activities of Granisetron.
GranisetronGranisetron may increase the serotonergic activities of Amoxapine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Amoxapine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Amoxapine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Amoxapine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Amoxapine.
HeroinHeroin may increase the serotonergic activities of Amoxapine.
HeroinThe risk or severity of adverse effects can be increased when Amoxapine is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Amoxapine.
HydracarbazineHydracarbazine may increase the serotonergic activities of Amoxapine.
HydrochlorothiazideAmoxapine may increase the hyponatremic activities of Hydrochlorothiazide.
HydrocodoneHydrocodone may increase the serotonergic activities of Amoxapine.
HydrocodoneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Hydrocodone.
HydroflumethiazideAmoxapine may increase the hyponatremic activities of Hydroflumethiazide.
HydromorphoneHydromorphone may increase the serotonergic activities of Amoxapine.
HydromorphoneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Hydromorphone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.
HydroxyzineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Hydroxyzine.
IbutilideAmoxapine may increase the QTc-prolonging activities of Ibutilide.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Amoxapine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Amoxapine.
IndalpineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Indalpine.
IndalpineIndalpine may increase the serotonergic activities of Amoxapine.
IndapamideAmoxapine may increase the hyponatremic activities of Indapamide.
IndenololThe serum concentration of Indenolol can be increased when it is combined with Amoxapine.
IndinavirThe metabolism of Amoxapine can be decreased when combined with Indinavir.
Insulin AspartAmoxapine may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirAmoxapine may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineAmoxapine may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineAmoxapine may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanAmoxapine may increase the hypoglycemic activities of Insulin Human.
Insulin LisproAmoxapine may increase the hypoglycemic activities of Insulin Lispro.
Ioflupane I-123Amoxapine may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IproclozideIproclozide may increase the serotonergic activities of Amoxapine.
IproniazidIproniazid may increase the serotonergic activities of Amoxapine.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Amoxapine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Amoxapine is combined with Isocarboxazid.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Amoxapine.
IsoniazidThe metabolism of Amoxapine can be decreased when combined with Isoniazid.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Amoxapine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Amoxapine.
KetobemidoneKetobemidone may increase the serotonergic activities of Amoxapine.
KetobemidoneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ketobemidone.
KetoconazoleThe metabolism of Amoxapine can be decreased when combined with Ketoconazole.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Amoxapine.
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Amoxapine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Amoxapine.
LanreotideAmoxapine may increase the hypoglycemic activities of Lanreotide.
LenvatinibAmoxapine may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideAmoxapine may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Amoxapine.
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Amoxapine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Amoxapine.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Amoxapine.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Amoxapine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Amoxapine.
LevofloxacinAmoxapine may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Amoxapine.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Amoxapine is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Amoxapine is combined with Levomilnacipran.
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Amoxapine.
LevorphanolLevorphanol may increase the serotonergic activities of Amoxapine.
LevorphanolThe risk or severity of adverse effects can be increased when Amoxapine is combined with Levorphanol.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Amoxapine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Amoxapine.
LinezolidLinezolid may increase the serotonergic activities of Amoxapine.
LinezolidThe risk or severity of adverse effects can be increased when Amoxapine is combined with Linezolid.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Amoxapine.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Amoxapine.
LiraglutideAmoxapine may increase the hypoglycemic activities of Liraglutide.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Amoxapine.
LofentanilLofentanil may increase the serotonergic activities of Amoxapine.
LofentanilThe risk or severity of adverse effects can be increased when Amoxapine is combined with Lofentanil.
LopinavirAmoxapine may increase the QTc-prolonging activities of Lopinavir.
LopinavirThe metabolism of Amoxapine can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Amoxapine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Amoxapine.
LorcaserinThe metabolism of Amoxapine can be decreased when combined with Lorcaserin.
LorcaserinThe risk or severity of adverse effects can be increased when Amoxapine is combined with Lorcaserin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Amoxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Amoxapine.
LumefantrineAmoxapine may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Amoxapine can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Amoxapine.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Amoxapine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Amoxapine.
MebanazineMebanazine may increase the serotonergic activities of Amoxapine.
MecaserminAmoxapine may increase the hypoglycemic activities of Mecasermin.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Amoxapine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Amoxapine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Amoxapine.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Amoxapine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Amoxapine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Amoxapine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Amoxapine.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Amoxapine.
MetforminAmoxapine may increase the hypoglycemic activities of Metformin.
MethadoneMethadone may increase the serotonergic activities of Amoxapine.
MethadoneAmoxapine may increase the QTc-prolonging activities of Methadone.
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Amoxapine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Amoxapine is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Amoxapine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Amoxapine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Amoxapine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Amoxapine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Amoxapine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Amoxapine.
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Amoxapine.
MethyclothiazideAmoxapine may increase the hyponatremic activities of Methyclothiazide.
Methylene blueAmoxapine may increase the serotonergic activities of Methylene blue.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Amoxapine.
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Amoxapine.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Amoxapine.
MetolazoneAmoxapine may increase the hyponatremic activities of Metolazone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Amoxapine.
MetoprololThe metabolism of Amoxapine can be decreased when combined with Metoprolol.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Amoxapine.
MetyrosineAmoxapine may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Amoxapine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Amoxapine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Amoxapine.
MifepristoneAmoxapine may increase the hypoglycemic activities of Mifepristone.
MiglitolAmoxapine may increase the hypoglycemic activities of Miglitol.
MilnacipranThe risk or severity of adverse effects can be increased when Amoxapine is combined with Milnacipran.
MilnacipranMilnacipran may increase the serotonergic activities of Amoxapine.
MinaprineMinaprine may increase the serotonergic activities of Amoxapine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.
MirabegronThe metabolism of Amoxapine can be decreased when combined with Mirabegron.
MirtazapineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Amoxapine.
MoclobemideMoclobemide may increase the serotonergic activities of Amoxapine.
MoclobemideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Moclobemide.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Amoxapine.
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Amoxapine.
MorphineMorphine may increase the serotonergic activities of Amoxapine.
MorphineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Morphine.
MoxifloxacinAmoxapine may increase the QTc-prolonging activities of Moxifloxacin.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.
NabiloneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Amoxapine.
NalbuphineNalbuphine may increase the serotonergic activities of Amoxapine.
NalbuphineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Nalbuphine.
NaratriptanThe risk or severity of adverse effects can be increased when Amoxapine is combined with Naratriptan.
NateglinideAmoxapine may increase the hypoglycemic activities of Nateglinide.
NefazodoneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Nefazodone.
NevirapineThe metabolism of Amoxapine can be decreased when combined with Nevirapine.
NialamideNialamide may increase the serotonergic activities of Amoxapine.
NicardipineThe metabolism of Amoxapine can be decreased when combined with Nicardipine.
NilotinibAmoxapine may increase the QTc-prolonging activities of Nilotinib.
NilotinibThe metabolism of Amoxapine can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Amoxapine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Amoxapine.
NormethadoneNormethadone may increase the serotonergic activities of Amoxapine.
NormethadoneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Amoxapine.
OctamoxinOctamoxin may increase the serotonergic activities of Amoxapine.
OctreotideAmoxapine may increase the hypoglycemic activities of Octreotide.
OfloxacinAmoxapine may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Amoxapine.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Amoxapine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Amoxapine.
OpiumOpium may increase the serotonergic activities of Amoxapine.
OpiumThe risk or severity of adverse effects can be increased when Amoxapine is combined with Opium.
OrphenadrineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Amoxapine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Amoxapine.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Amoxapine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Amoxapine.
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Amoxapine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Amoxapine.
OxycodoneOxycodone may increase the serotonergic activities of Amoxapine.
OxycodoneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Oxycodone.
OxymorphoneOxymorphone may increase the serotonergic activities of Amoxapine.
OxymorphoneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Oxymorphone.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Amoxapine.
PalonosetronPalonosetron may increase the serotonergic activities of Amoxapine.
PanobinostatAmoxapine may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Amoxapine can be decreased when combined with Panobinostat.
ParaldehydeAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Amoxapine.
PargylinePargyline may increase the serotonergic activities of Amoxapine.
ParoxetineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Paroxetine.
ParoxetineParoxetine may increase the serotonergic activities of Amoxapine.
PasireotideAmoxapine may increase the hypoglycemic activities of Pasireotide.
PazopanibAmoxapine may increase the QTc-prolonging activities of Pazopanib.
Peginterferon alfa-2bThe serum concentration of Amoxapine can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Amoxapine.
PentamidineAmoxapine may increase the hypoglycemic activities of Pentamidine.
PentazocinePentazocine may increase the serotonergic activities of Amoxapine.
PentazocineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Amoxapine.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Amoxapine.
PerflutrenAmoxapine may increase the QTc-prolonging activities of Perflutren.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Amoxapine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Amoxapine.
PethidinePethidine may increase the serotonergic activities of Amoxapine.
PethidineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Pethidine.
PhenelzinePhenelzine may increase the serotonergic activities of Amoxapine.
PhenelzineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Phenelzine.
PhenindioneAmoxapine may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the serotonergic activities of Amoxapine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Amoxapine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Amoxapine.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Amoxapine.
PhenprocoumonAmoxapine may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Amoxapine.
PimozideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Pimozide.
PindololThe serum concentration of Pindolol can be increased when it is combined with Amoxapine.
PioglitazoneAmoxapine may increase the hypoglycemic activities of Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Amoxapine.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Amoxapine.
PirlindolePirlindole may increase the serotonergic activities of Amoxapine.
PivhydrazinePivhydrazine may increase the serotonergic activities of Amoxapine.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Amoxapine.
PolythiazideAmoxapine may increase the hyponatremic activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Amoxapine.
PractololThe serum concentration of Practolol can be increased when it is combined with Amoxapine.
PramipexoleAmoxapine may increase the sedative activities of Pramipexole.
PramlintideAmoxapine may increase the hypoglycemic activities of Pramlintide.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Amoxapine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Amoxapine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Amoxapine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Amoxapine.
PrimaquineAmoxapine may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Amoxapine.
ProcainamideAmoxapine may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Amoxapine.
ProcarbazineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Procarbazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amoxapine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Amoxapine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Amoxapine.
PropafenoneAmoxapine may increase the QTc-prolonging activities of Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Amoxapine.
PropericiazineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Amoxapine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Amoxapine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Amoxapine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Amoxapine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Amoxapine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Amoxapine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amoxapine.
QuinethazoneAmoxapine may increase the hyponatremic activities of Quinethazone.
QuinidineAmoxapine may increase the QTc-prolonging activities of Quinidine.
QuinidineThe metabolism of Amoxapine can be decreased when combined with Quinidine.
QuinineAmoxapine may increase the hypoglycemic activities of Quinine.
QuinineThe metabolism of Amoxapine can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Amoxapine.
RanolazineThe metabolism of Amoxapine can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the serotonergic activities of Amoxapine.
RasagilineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Rasagiline.
RemifentanilRemifentanil may increase the serotonergic activities of Amoxapine.
RemifentanilThe risk or severity of adverse effects can be increased when Amoxapine is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Amoxapine.
RepaglinideAmoxapine may increase the hypoglycemic activities of Repaglinide.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Amoxapine.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Amoxapine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Amoxapine.
RitonavirThe metabolism of Amoxapine can be decreased when combined with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Amoxapine is combined with Rizatriptan.
RolapitantThe metabolism of Amoxapine can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Amoxapine.
RopiniroleAmoxapine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Amoxapine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Amoxapine.
RosiglitazoneAmoxapine may increase the hypoglycemic activities of Rosiglitazone.
RotigotineAmoxapine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Amoxapine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Amoxapine.
SafrazineSafrazine may increase the serotonergic activities of Amoxapine.
SaquinavirAmoxapine may increase the QTc-prolonging activities of Saquinavir.
SaxagliptinAmoxapine may increase the hypoglycemic activities of Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Amoxapine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Amoxapine.
SelegilineSelegiline may increase the serotonergic activities of Amoxapine.
SelegilineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Selegiline.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Amoxapine.
SertralineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Sertraline.
SertralineThe metabolism of Amoxapine can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amoxapine.
SitagliptinAmoxapine may increase the hypoglycemic activities of Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Amoxapine.
SotalolThe serum concentration of Sotalol can be increased when it is combined with Amoxapine.
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Amoxapine.
SufentanilSufentanil may increase the serotonergic activities of Amoxapine.
SufentanilThe risk or severity of adverse effects can be increased when Amoxapine is combined with Sufentanil.
SulfadiazineAmoxapine may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleAmoxapine may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleAmoxapine may increase the hypoglycemic activities of Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Amoxapine.
SumatriptanThe risk or severity of adverse effects can be increased when Amoxapine is combined with Sumatriptan.
SunitinibAmoxapine may increase the hypoglycemic activities of Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Amoxapine.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Amoxapine.
TapentadolTapentadol may increase the serotonergic activities of Amoxapine.
TapentadolThe risk or severity of adverse effects can be increased when Amoxapine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Amoxapine.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Amoxapine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Amoxapine is combined with Tedizolid Phosphate.
TelavancinAmoxapine may increase the QTc-prolonging activities of Telavancin.
TelithromycinAmoxapine may increase the QTc-prolonging activities of Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Amoxapine.
TerbinafineThe metabolism of Amoxapine can be decreased when combined with Terbinafine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Amoxapine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Amoxapine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Amoxapine.
ThalidomideAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Amoxapine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Amoxapine.
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Amoxapine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Amoxapine.
ThioproperazineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Thioproperazine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Amoxapine.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Amoxapine.
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Amoxapine.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Amoxapine.
TiclopidineThe metabolism of Amoxapine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Amoxapine.
TimololThe serum concentration of Timolol can be increased when it is combined with Amoxapine.
TipranavirThe metabolism of Amoxapine can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Amoxapine.
TolazamideAmoxapine may increase the hypoglycemic activities of Tolazamide.
TolbutamideAmoxapine may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Amoxapine.
ToloxatoneToloxatone may increase the serotonergic activities of Amoxapine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Amoxapine.
ToremifeneAmoxapine may increase the QTc-prolonging activities of Toremifene.
TramadolTramadol may increase the serotonergic activities of Amoxapine.
TramadolThe risk or severity of adverse effects can be increased when Amoxapine is combined with Tramadol.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Amoxapine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineTranylcypromine may increase the serotonergic activities of Amoxapine.
TranylcypromineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Amoxapine.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Amoxapine.
TrichlormethiazideAmoxapine may increase the hyponatremic activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Amoxapine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Amoxapine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Amoxapine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Amoxapine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Amoxapine.
VandetanibAmoxapine may increase the QTc-prolonging activities of Vandetanib.
VemurafenibAmoxapine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Amoxapine can be decreased when combined with Venlafaxine.
VenlafaxineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Venlafaxine.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Amoxapine.
VilazodoneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Vilazodone.
VilazodoneVilazodone may increase the serotonergic activities of Amoxapine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Amoxapine.
WarfarinAmoxapine may increase the anticoagulant activities of Warfarin.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Amoxapine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Amoxapine.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Amoxapine.
ZimelidineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Zimelidine.
ZimelidineZimelidine may increase the serotonergic activities of Amoxapine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Amoxapine.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Amoxapine.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Amoxapine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Amoxapine.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Amoxapine.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Amoxapine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Amoxapine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Amoxapine.
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Spurlock G, Buckland P, O'Donovan M, McGuffin P: Lack of effect of antidepressant drugs on the levels of mRNAs encoding serotonergic receptors, synthetic enzymes and 5HT transporter. Neuropharmacology. 1994 Mar-Apr;33(3-4):433-40. [PubMed:7984281 ]
  2. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Wei HB, Niu XY: [Comparison of the affinities of amoxapine and loxapine for various receptors in rat brain and the receptor down-regulation after chronic administration]. Yao Xue Xue Bao. 1990;25(12):881-5. [PubMed:1966571 ]
  2. Nasu R, Matsuo H, Takanaga H, Ohtani H, Sawada Y: Quantitative prediction of catalepsy induced by amoxapine, cinnarizine and cyclophosphamide in mice. Biopharm Drug Dispos. 2000 May;21(4):129-38. [PubMed:11180191 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Nasu R, Matsuo H, Takanaga H, Ohtani H, Sawada Y: Quantitative prediction of catalepsy induced by amoxapine, cinnarizine and cyclophosphamide in mice. Biopharm Drug Dispos. 2000 May;21(4):129-38. [PubMed:11180191 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881 ]
  2. Buckley NA, McManus PR: Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug Saf. 1998 May;18(5):369-81. [PubMed:9589848 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Wei HB, Niu XY: [Comparison of the affinities of amoxapine and loxapine for various receptors in rat brain and the receptor down-regulation after chronic administration]. Yao Xue Xue Bao. 1990;25(12):881-5. [PubMed:1966571 ]
  2. Buckley NA, McManus PR: Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug Saf. 1998 May;18(5):369-81. [PubMed:9589848 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Richelson E: Antimuscarinic and other receptor-blocking properties of antidepressants. Mayo Clin Proc. 1983 Jan;58(1):40-6. [PubMed:6130192 ]
  2. Buckley NA, McManus PR: Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug Saf. 1998 May;18(5):369-81. [PubMed:9589848 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Buckley NA, McManus PR: Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug Saf. 1998 May;18(5):369-81. [PubMed:9589848 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Palvimaki EP, Roth BL, Majasuo H, Laakso A, Kuoppamaki M, Syvalahti E, Hietala J: Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berl). 1996 Aug;126(3):234-40. [PubMed:8876023 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Glusa E, Pertz HH: Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT(2B) receptors. Br J Pharmacol. 2000 Jun;130(3):692-8. [PubMed:10821800 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10. [PubMed:7908055 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10. [PubMed:7908055 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR: Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther. 2005 Dec;315(3):1278-87. Epub 2005 Aug 31. [PubMed:16135699 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR: Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther. 2005 Dec;315(3):1278-87. Epub 2005 Aug 31. [PubMed:16135699 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Components:
NameUniProt IDDetails
Alpha-1A adrenergic receptorP35348 Details
Alpha-1B adrenergic receptorP35368 Details
Alpha-1D adrenergic receptorP25100 Details
References
  1. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Components:
NameUniProt IDDetails
Muscarinic acetylcholine receptor M1P11229 Details
Muscarinic acetylcholine receptor M2P08172 Details
Muscarinic acetylcholine receptor M3P20309 Details
Muscarinic acetylcholine receptor M4P08173 Details
Muscarinic acetylcholine receptor M5P08912 Details
References
  1. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins ...
Gene Name:
HTR2B
Uniprot ID:
P41595
Molecular Weight:
54297.41 Da
References
  1. Glusa E, Pertz HH: Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT(2B) receptors. Br J Pharmacol. 2000 Jun;130(3):692-8. [PubMed:10821800 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Gozlan H, Saddiki-Traki F, Merahi N, Laguzzi R, Hamon M: [Preclinical pharmacology of amoxapine and amitriptyline. Implications of serotoninergic and opiodergic systems in their central effect in rats]. Encephale. 1991 Dec;17 Spec No 3:415-22. [PubMed:1666997 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Gozlan H, Saddiki-Traki F, Merahi N, Laguzzi R, Hamon M: [Preclinical pharmacology of amoxapine and amitriptyline. Implications of serotoninergic and opiodergic systems in their central effect in rats]. Encephale. 1991 Dec;17 Spec No 3:415-22. [PubMed:1666997 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Gozlan H, Saddiki-Traki F, Merahi N, Laguzzi R, Hamon M: [Preclinical pharmacology of amoxapine and amitriptyline. Implications of serotoninergic and opiodergic systems in their central effect in rats]. Encephale. 1991 Dec;17 Spec No 3:415-22. [PubMed:1666997 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol.
Components:
NameUniProt IDDetails
Alpha-2A adrenergic receptorP08913 Details
Alpha-2B adrenergic receptorP18089 Details
Alpha-2C adrenergic receptorP18825 Details
References
  1. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Histamine receptor activity
Specific Function:
The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues. Displays a significant level of constitutive activity (spontaneous activity in the absence of agonist).
Gene Name:
HRH4
Uniprot ID:
Q9H3N8
Molecular Weight:
44495.375 Da
References
  1. Lim HD, van Rijn RM, Ling P, Bakker RA, Thurmond RL, Leurs R: Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. J Pharmacol Exp Ther. 2005 Sep;314(3):1310-21. Epub 2005 Jun 9. [PubMed:15947036 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. Wei HB, Niu XY: [Comparison of the affinities of amoxapine and loxapine for various receptors in rat brain and the receptor down-regulation after chronic administration]. Yao Xue Xue Bao. 1990;25(12):881-5. [PubMed:1966571 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
  2. PDSP Ki Database [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Shin HC, Kim HR, Cho HJ, Yi H, Cho SM, Lee DG, Abd El-Aty AM, Kim JS, Sun D, Amidon GL: Comparative gene expression of intestinal metabolizing enzymes. Biopharm Drug Dispos. 2009 Nov;30(8):411-21. doi: 10.1002/bdd.675. [PubMed:19746353 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23